Rifaximin

Generic Name: Rifaximin

Brand Names: Xifaxan, Zaxine

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₁N_₃O_₁₁

CAS Number: 80621-81-4

Unique Ingredient Identifier: L36O5T016N

Background: Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

Indication: Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.

Associated Conditions: Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea

Clinical Trials

Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Phase 4

Recruiting

Conditions: Diarrhoea;Acute
Diarrhea Travelers

Interventions: Drug: Azithromycin 500 MG
Drug: Rifaximin 550 MG
Drug: Loperamide

First Posted Date: 2023-01-10

Last Posted Date: 2024-12-10

Lead Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

Target Recruit Count: 150

Registration Number: NCT05677282

Locations: 🇩🇯
Camp Lemonnier Djibouti, Djibouti, Djibouti
🇭🇳
JTF-Bravo, Soto Cano AB, Comayagua, Honduras
🇰🇪
British Army Training Site UK, Nanyuki, Kenya

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

Phase 2

Completed

Conditions: Ascites Infection

Interventions: Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN]

First Posted Date: 2022-11-17

Last Posted Date: 2022-11-21

Lead Sponsor: Samar Atef Sebaweh Mohammed

Target Recruit Count: 104

Registration Number: NCT05621005

Locations: 🇪🇬
faculty of medicine Ain Shams university, Cairo, Egypt

Effects of Rifaximin on Gut Microbiota and Emotion

Phase 2

Recruiting

Conditions: Healthy Volunteers
Stress
Fear

Interventions: Dietary Supplement: Placebo
Drug: Rifaximin

First Posted Date: 2022-10-19

Last Posted Date: 2024-12-20

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 60

Registration Number: NCT05587036

Locations: 🇧🇪
UZ/KU Leuven, Leuven, Belgium

Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

Phase 1

Recruiting

Conditions: Irritable Bowel Syndrome With Diarrhea

Interventions: Drug: Nitazoxanide 500Mg Oral Tablet
Drug: Rifaximin 550Mg Tab

First Posted Date: 2022-07-12

Last Posted Date: 2023-11-21

Lead Sponsor: Sadat City University

Target Recruit Count: 84

Registration Number: NCT05453916

Locations: 🇪🇬
Faculty of Pharmacy, University of Sadat city, Sadat City, Menoufia, Egypt

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

Phase 2

Not yet recruiting

Conditions: Cystic Fibrosis
Abdominal Pain
Small Bowel Disease

Interventions: Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN]
Drug: Placebo

First Posted Date: 2022-06-07

Last Posted Date: 2025-02-27

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 100

Registration Number: NCT05408910

Locations: 🇺🇸
Atrium Health, Charlotte, North Carolina, United States

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Phase 3

Active, not recruiting

Conditions: Hepatic Encephalopathy

Interventions: Drug: Placebo
Drug: Rifaximin SSD

First Posted Date: 2022-03-28

Last Posted Date: 2024-05-09

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 466

Registration Number: NCT05297448

Locations: 🇺🇸
Bausch Site 482, Valencia, California, United States
🇺🇸
Bausch Site 452, Miami Lakes, Florida, United States
🇺🇸
Bausch Site 577, Macon, Georgia, United States

and more 184 locations

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

Phase 1

Recruiting

Conditions: Human Gastrointestinal Physiology Data

Interventions: Drug: Glucotrol XL 5Mg Extended-Release Tablet
Drug: Glipizide ER 5 MG 24 HR Extended Release Oral Tablet
Drug: Rifaximin 200Mg Tab
Drug: 13C6-Glipizide

First Posted Date: 2021-12-16

Last Posted Date: 2025-01-29

Lead Sponsor: University of Michigan

Target Recruit Count: 40

Registration Number: NCT05159427

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Phase 2

Completed

Conditions: Papulopustular Rosacea

Interventions: Drug: Rifaximin
Drug: Placebo

First Posted Date: 2021-12-09

Last Posted Date: 2024-04-24

Lead Sponsor: Alfasigma S.p.A.

Target Recruit Count: 216

Registration Number: NCT05150587

Locations: 🇺🇸
Skin Care Research, Boca Raton, Florida, United States
🇺🇸
Metropolis Dermatology, Los Angeles, California, United States
🇺🇸
DelRicht Research, Tulsa, Oklahoma, United States

and more 32 locations

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Phase 3

Active, not recruiting

Conditions: Hepatic Encephalopathy

Interventions: Drug: Placebo
Drug: Rifaximin SSD

First Posted Date: 2021-10-08

Last Posted Date: 2024-03-22

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 524

Registration Number: NCT05071716

Locations: 🇺🇸
Bausch Site 219, Atlanta, Georgia, United States
🇺🇸
Bausch Site 140, Los Angeles, California, United States
🇺🇸
Bausch Site 189, Los Angeles, California, United States

and more 147 locations

Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.

Not Applicable

Recruiting

Conditions: Small Intestinal Bacterial Overgrowth

Interventions: Device: Atmo Gas Capsule
Procedure: Jejunal Aspiration and culture
Diagnostic Test: Glucose Breath Test
Diagnostic Test: Fructoolifosaccharides (FOS) Breath Test
Drug: Placebo
Drug: Rifaximin

First Posted Date: 2021-06-02

Last Posted Date: 2024-01-30

Lead Sponsor: Atmo Biosciences Pty Ltd

Target Recruit Count: 150

Registration Number: NCT04910815

Locations: 🇮🇳
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy